According to SNS Insider, the global Non-Alcoholic Steatohepatitis Treatment Market was valued at $7.70 billion in 2024 and is projected to reach $55.52 billion by 2032 with a CAGR of 28.05% from 2025 ...

Fatty Liver Alliance advocates about the importance of 2 new NASH treatments soon to be approved. ICER welcomes public comments and discussion about new NASH drugs. NASH: Gastric bypass, diet, ...

FDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH Boehringer ...

Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Resmetirom ...

The NASH treatment market will have significant dependence on two underappreciated indirect factors that are largely undetermined at this point. The size of the addressable NASH market will depend on ...

AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s recent clinical study, officially titled A ...

The FDA decision follows the Company’s Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed in August 2021 The FDA’s dedicated Fast Track program is designed to ...

BOSTON--(BUSINESS WIRE)--Care Access—a global research site enabling clinical research participation for more people—is actively enrolling participants at its Pottsville, Pa., location to study the ...

Companies in clinical development with drugs for the fatty liver disease NASH are all testing chronic treatments—medicines either injected or taken orally on a regular basis. Gene therapy offers the ...

Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-tolerated Corcept ...

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral ...